Combination for use in the treatment of lung cancer
AssigneeLDN Pharma Limited
InventorsAngus Dalgleish, Wai Lui
Life of this patent
Estimating the term…
Abstract
The invention is based on the finding that co-administration of 6-β-naltrexol alongside vitamin D together with a chemotherapeutic agent, results in a further reduction in lung cancer cell growth. The combination of 6-β-naltrexol with vitamin D results in a greater decrease in the growth of cancer cells compared to the sum of the effects of each agent when administered in isolation.
Claims14
A method of treating lung cancer comprising administering 6-β-naltrexol sequentially, separately or simultaneously with vitamin D or an active metabolite thereof to a subject having lung cancer.
A method for the treatment of a subject with lung cancer, comprising administering a therapeutically effective amount of 6-β-naltrexol, wherein the subject is also administered vitamin D or an active metabolite thereof.
Dependencies are inferred from the claim text.